Breadcrumb
2009-06-19
IQWiG in dialogue
Assessing benefit without considering harm?
In addition to assessing desirable effects and (additional) benefit, IQWiG is also required by law to assess the possible harm of medical interventions. However, assessing the harm of therapies is not as well defined in systematic reviews and HTA reports as assessing the benefit. Consequently in 2009 "IQWiG in dialogue" addressed various aspects concerned with assessing harmful effects.
Presentations (German):
Introduction to the topic "Assessing benefit without considering harm? Prof. Dr. Ralf Bender
Interpreting poor quality results on adverse events within the framework of systematic reviews using the example of studies on benign prostatic hyperplasia Dr. Gudio Skipka
Assessing harm within the framework of the benefit assessment of drugs Dr. Beate Wieseler
Benefit-harm assessment of drugs following authorisation Dr. Ulrich Hagemann (Federal Institute for Drugs and Medical Devices, BfArM)
Benefit and harm of drugs ? both sides of the coin. Reflections on assessments ?who carries them out, when and how? Dr. Dr. Norbert Banik (GlaxoSmithKline GmbH & Co. KG)
